The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria

Overview

Journal Drugs

Specialty Pharmacology

Date 2017 May 1

PMID 28456943

Citations 9

Authors

Grace Li

Joseph F Standing

Julia Bielicki

William Hope

John van den Anker

Paul T Heath

Mike Sharland

Affiliations

Soon will be listed here.

Abstract

The broad-spectrum activity of fosfomycin, including against multidrug-resistant (MDR) strains, has led to renewed interest in its use in recent years. Neonatal sepsis remains a substantial cause of morbidity and mortality at a global level, with evidence that MDR bacteria play an increasing role. The evidence for use of fosfomycin in neonatal subjects is limited. We summarise current knowledge of the pharmacokinetics and clinical outcomes for the use of fosfomycin in neonatal sepsis and issues specific to neonatal physiology. While fosfomycin has a broad range of coverage, we evaluate the extent to which it may be effective against MDR bacteria in a neonatal setting, in light of recent evidence suggesting it to be most effective when administered in combination with other antibiotics. Given the urgency of clinical demand for treatment of MDR bacterial sepsis, we outline directions for further work, including the need for future clinical trials in this at-risk population.

Citing Articles

Reintroduction of Legacy Antibiotics in Neonatal Sepsis: The Special Role of Fosfomycin and Colistin.

Baltogianni M, Dermitzaki N, Kosmeri C, Serbis A, Balomenou F, Giapros V Antibiotics (Basel). 2024; 13(4).

PMID: 38667009 PMC: 11047481. DOI: 10.3390/antibiotics13040333.

Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment.

Kowalska-Krochmal B, Maczynska B, Ruranska-Smutnicka D, Secewicz A, Krochmal G, Bartelak M Pathogens. 2022; 11(12).

PMID: 36558775 PMC: 9786176. DOI: 10.3390/pathogens11121441.

Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload.

Obiero C, Williams P, Murunga S, Thitiri J, Omollo R, Walker A Arch Dis Child. 2022; 107(9):802-810.

PMID: 35078765 PMC: 9411916. DOI: 10.1136/archdischild-2021-322483.

Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.

Darlow C, da Costa R, Ellis S, Franceschi F, Sharland M, Piddock L Paediatr Drugs. 2021; 23(5):465-484.

PMID: 34435316 PMC: 8418595. DOI: 10.1007/s40272-021-00465-z.

Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS).

Thomson K, Dyer C, Liu F, Sands K, Portal E, Carvalho M Lancet Infect Dis. 2021; 21(12):1677-1688.

PMID: 34384533 PMC: 8612937. DOI: 10.1016/S1473-3099(21)00050-5.

References

Sauermann R, Karch R, Langenberger H, Kettenbach J, Mayer-Helm B, Petsch M . Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother. 2005; 49(11):4448-54. PMC: 1280140. DOI: 10.1128/AAC.49.11.4448-4454.2005. View

Bielicki J, Lundin R, Sharland M . Antibiotic Resistance Prevalence in Routine Bloodstream Isolates from Children's Hospitals Varies Substantially from Adult Surveillance Data in Europe. Pediatr Infect Dis J. 2015; 34(7):734-41. DOI: 10.1097/INF.0000000000000652. View

Sultan A, Rizvi M, Khan F, Sami H, Shukla I, Khan H . Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer?. Urol Ann. 2015; 7(1):26-30. PMC: 4310112. DOI: 10.4103/0974-7796.148585. View

Sahni R, Balaji V, Varghese R, John J, Tansarli G, Falagas M . Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study. Future Microbiol. 2013; 8(5):675-80. DOI: 10.2217/fmb.13.31. View

Guibert M, Magny J, Poudenx F, Lebrun L, Dehan M . [Comparative pharmacokinetics of fosfomycin in the neonate: 2 modes of administration]. Pathol Biol (Paris). 1987; 35(5 Pt 2):750-2. View

de Man P, Verhoeven B, Verbrugh H, Vos M, van den Anker J . An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000; 355(9208):973-8. DOI: 10.1016/s0140-6736(00)90015-1. View

VanScoy B, McCauley J, Bhavnani S, Ellis-Grosse E, Ambrose P . Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model. Antimicrob Agents Chemother. 2016; 60(9):5141-5. PMC: 4997836. DOI: 10.1128/AAC.00355-16. View

Karageorgopoulos D, Wang R, Yu X, Falagas M . Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2011; 67(2):255-68. DOI: 10.1093/jac/dkr466. View

Michalopoulos A, Livaditis I, Gougoutas V . The revival of fosfomycin. Int J Infect Dis. 2011; 15(11):e732-9. DOI: 10.1016/j.ijid.2011.07.007. View

10.

Traunmuller F, Popovic M, Konz K, Vavken P, Leithner A, Joukhadar C . A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates. Clin Pharmacokinet. 2011; 50(8):493-503. DOI: 10.2165/11592670-000000000-00000. View

11.

Stoll B, Hansen N, Sanchez P, Faix R, Poindexter B, Van Meurs K . Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics. 2011; 127(5):817-26. PMC: 3081183. DOI: 10.1542/peds.2010-2217. View

12.

Folgori L, Livadiotti S, Carletti M, Bielicki J, Pontrelli G, Ciofi Degli Atti M . Epidemiology and clinical outcomes of multidrug-resistant, gram-negative bloodstream infections in a European tertiary pediatric hospital during a 12-month period. Pediatr Infect Dis J. 2014; 33(9):929-32. DOI: 10.1097/INF.0000000000000339. View

13.

Taylor C, Mascaros E, Roman J, Paz M, Santos M, Munoz A . Enteropathogenic E. coli gastroenterocolitis in neonates treated with fosfomycin. Chemotherapy. 1977; 23 Suppl 1:310-4. DOI: 10.1159/000222068. View

14.

Le Doare K, Bielicki J, Heath P, Sharland M . Systematic Review of Antibiotic Resistance Rates Among Gram-Negative Bacteria in Children With Sepsis in Resource-Limited Countries. J Pediatric Infect Dis Soc. 2015; 4(1):11-20. DOI: 10.1093/jpids/piu014. View

15.

Cao X, Shen H, Xu Y, Xu X, Zhang Z, Cheng L . High prevalence of fosfomycin resistance gene fosA3 in bla CTX-M-harbouring Escherichia coli from urine in a Chinese tertiary hospital during 2010-2014. Epidemiol Infect. 2016; 145(4):818-824. PMC: 9507793. DOI: 10.1017/S0950268816002879. View

16.

Rossignol S, Regnier C . [Fosfomycin in severe infection in neonatology]. Ann Pediatr (Paris). 1984; 31(5):437-44. View

17.

Castaneda-Garcia A, Blazquez J, Rodriguez-Rojas A . Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance. Antibiotics (Basel). 2016; 2(2):217-36. PMC: 4790336. DOI: 10.3390/antibiotics2020217. View

18.

Gouyon J, Francois C, Semama D, Sandre D, Duez J, Portier H . [Nosocomial Staphylococcus epidermidis and Staphylococcus aureus septicemias in neonates]. Ann Pediatr (Paris). 1990; 37(1):21-5. View

19.

Pogue J, Marchaim D, Abreu-Lanfranco O, Sunkara B, Mynatt R, Zhao J . Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10. J Antibiot (Tokyo). 2013; 66(10):625-7. DOI: 10.1038/ja.2013.56. View

20.

Seale A, Head M, Fitchett E, Vergnano S, Saha S, Heath P . Neonatal infection: a major burden with minimal funding. Lancet Glob Health. 2015; 3(11):e669-70. DOI: 10.1016/S2214-109X(15)00204-1. View